DNA damage is a universal inducer of cell cycle arrest at the G 2 phase. Infection by the human immunodeficiency virus type 1 (HIV-1) also blocks cellular proliferation at the G 2 phase. The HIV-1 accessory gene vpr encodes a conserved 96-amino acid protein (Vpr) that is necessary and sufficient for the HIV-1-induced block of cellular proliferation. In the present study, we examined a recently identified DNA damage-signaling protein, the ATM-and Rad3-related protein, ATR, for its potential role in the induction of G 2 arrest by Vpr. We show that inhibition of ATR by pharmacological inhibitors, by expression of the dominant-negative form of ATR, or by RNA interference inhibits Vpr-induced cell cycle arrest. As with DNA damage, activation of ATR by Vpr results in phosphorylation of Chk1. This study provides conclusive evidence of activation of the ATR-initiated DNA damage-signaling pathway by a viral gene product. These observations are important toward understanding how HIV infection promotes cell cycle disruption, cell death, and ultimately, CD4؉ lymphocyte depletion.
DNA damage-signaling pathways consist of a network of interacting and occasionally redundant signals that may lead to the inactivation of the Cdc2-cyclin B complex (1) (2) (3) (4) (5) and cell cycle arrest in G 2 . A major point of regulation of the Cdc2-cyclin B cyclin complex is through inhibitory phosphorylation of Cdc2 on Tyr-15. Phosphorylation of the adjacent residue, Thr-14, also contributes to the inhibition of Cdc2 activity. Cdc25C is a dual specificity phosphatase that dephosphorylates Cdc2 on both Tyr-15 and Thr-14, leading to Cdc2 activation. Upon induction of the DNA damage checkpoint Cdc25C is inactivated through the actions of several kinases, including Chk1 and Chk2, which are under the control of the phosphatidylinositol 3-kinase-like proteins ATR and ATM.
ATR and ATM respond to a variety of abnormal DNA structures and initiate a signaling cascade leading to a DNA damage checkpoint (6) . Their roles are partially redundant but with some important distinctions both with regard to substrate preference and the types of the DNA damage to which the kinases respond. In response to genotoxic stress, ATM is responsible for phosphorylation of the Chk2 protein kinase, whereas ATR phosphorylates Chk1. ATR is primarily responsible for enforcement of the cell cycle checkpoint activated in response to intra-S-phase genotoxic stress, as exemplified by stalled replication forks and topoisomerase inhibition (7, 8) . In contrast, ATM is more important for the ionizing radiation-induced DNA damage checkpoint. Both proteins are inhibited by methylxanthines, such as caffeine. ATR acts in concert with Rad17 and the proliferating cell nuclear antigen-like heterotrimer composed of Rad9, Hus1, and Rad1 to enforce the DNA damage checkpoint (9 -11) .
ATR deletion is lethal early in embryogenesis (12, 13) . Therefore, in mammalian cells, ATR function must be studied by the introduction of an ATR kinase inactive mutant (14 -16) in an inducible manner or by transient knockdown of ATR expression via RNA interference (RNAi).
Several human viruses including reovirus (17) , human Papillomavirus (18) , and the human and simian immunodeficiency viruses (19) encode genes that activate the G 2 checkpoint. The induction of cell cycle arrest by the HIV-1 1 vpr-related genes of primate lentiviruses have been most extensively studied (20 -25) . Vpr-induced G 2 arrest leads to moderate transactivation of the HIV-1 promoter, the long terminal repeat (LTR) (26 -29) . The G 2 phase arrest and subsequent apoptosis may explain aspects of the CD4ϩ cell death in HIV infection.
Early studies demonstrated that Vpr-induced G 2 arrest is associated with inactivation of the cyclin-dependent kinase, Cdc2, by hyperphosphorylation and concomitant suppression of Cdc2-cyclin B kinase activity that is necessary for the G 2 to M transition (21) (22) (23) . In response to Vpr, the Cdc2-specific phosphatase, Cdc25C, is hyperphosphorylated in a pattern consistent with inactivation (21) . Induction of G 2 arrest by Vpr can be overcome by methylxanthines (27, 30) . Together, the above observations have led to the suggestion that Vpr induces cell cycle arrest via a DNA damage-sensitive pathway (30) , although the precise signaling pathway has remained elusive. A direct binding of Vpr to DNA has been reported (31) . However the possibility that Vpr activates DNA damage-dependent cellular pathways by directly causing alterations in the structure or the integrity of DNA has not been demonstrated. Bartz et al. (32) showed that Vpr-induced G 2 arrest is independent of ATM function. In addition, p53, which is associated with key aspects of the DNA damage response, is not necessary for the vpr-mediated cell cycle arrest or apoptosis (24) . In this work, we examined the potential involvement of the DNA dam-age-signaling pathway that is initiated by ATR in vpr-induced G 2 arrest.
EXPERIMENTAL PROCEDURES
Cell Lines-Human cervical cancer cell line HeLa and transformed human embryonic kidney cell line HEK293T were grown in Dulbecco's modified Eagle's medium 10% fetal bovine serum. Human SV40 transformed fibroblasts GM847/ATRkd (a generous gift of Dr. Cimprich, Stanford University and Dr. Handeli, University of Washington) and human osteosarcoma-derived U2OS ATRkd cell lines were maintained in Dulbecco's modified Eagle's medium, 10% fetal bovine serum with 400 g/ml G418 and 200 g/ml hygromycin B.
Plasmids-We described the lentiviral vector, pHR-GFP, in a previous report (33) . pHR-VPR was derived by substituting the B7.1 cDNA in place of human T-cell lymphotrophic virus-I tax in the vector pHRЈCMV/Tax1/eGFP (34) . This was accomplished by digesting pCMVvpr (19) with NotI followed by Klenow treatment and further digestion with XhoI. We then ligated the vpr-containing band to pHRЈCMV/Tax1/ eGFP, which was previously digested with SalI, treated with Klenow, and further digested with XhoI.
Viral Vector Production and Titration-Lentiviral vectors were produced by transient transfection of HEK293T cells. For defective lentivirus vector production, pHR-GFP and pHR-VPR plasmids were cotransfected with pCMVD8.2⌬Vpr (35) and pHCMV-VSVG (36) using calcium phosphate-mediated transfection (27) . Virus supernatant was collected at 48, 72, and 96 h post-transfection. Harvested supernatants were cleared by centrifugation at 2,000 rpm and frozen at Ϫ80°C. Vector titers were measured by infection of HeLa cells as described below followed by flow cytometric analysis of cells positive for the reporter molecule, green fluorescent protein (GFP). Vector titers were calculated as Titer ϭ (F ϫ C 0 / V) ϫ D, where F is the frequency of GFP (ϩ) cells by flow cytometry, C 0 is the total number of target cells at the time of infection, V is the volume of inoculum, and D is the virus dilution factor. Virus dilution factor used for titrations was D ϭ 10. Total number of target cells at the time of infection was 10 6 . Cell Cycle Analysis-Cells were infected with either pHR-VPR or pHR-GFP at a multiplicity of infection of 2.5 to achieve greater than a 90% infection rate was as measured by counting GFP-positive cells. Cells were detached with 2 mM EDTA, washed in phosphate-buffered saline, fixed with 70% ethanol for over 18 h at Ϫ20°C, then stained with propidium iodide solution for 30 min at 4°C (20 g/ml propidium iodide, 11.25 kunitz units/ml RNase A in phosphate-buffered saline). If Ͻ90% infection was achieved the cells were fixed in 0.25% paraformaldehyde for 1 h to preserve GFP fluorescence, and only the GFP-positive cells were gated to represent the infected fraction of the cells. Flow cytometric analysis was performed in an Epics Elite ESP (Coulter Corp., Hialeah, FL). Cell cycle analysis was performed using Multicycle AV software (Phoenix Flow Systems, San Diego, CA). All cell cycle experiments were performed at least three times, and typical results are shown.
Drug Treatments-LY294002 (Cell Signaling Technology, Beverly, MA) was used at 50 M. Caffeine (Sigma) was used at 2.5 mM. Doxorubicin (Sigma) was used at 4 M. Taxol was used at 25 nM. UCN-01 (NSC 638850) was obtained from Developmental Therapeutics Program at the National Cancer Institute and used at 300 nM.
Western Blot-HeLa cells were washed in phosphate-buffered saline and lysed in modified radioimmune precipitation assay buffer (Cell Signaling Research, Beverly, MA). Protein concentration in the lysate was obtained using a modified Lowry method using Bio-Rad protein assay II kit, catalog number 500 -002. 100 g of protein were loaded onto a 10% SDS-PAGE gel and electrophoretically transferred to a polyvinylidene difluoride membrane. The membranes were blocked in Tris-buffered saline, 0.2% Tween 20, and 5% nonfat dry milk and probed with monoclonal antibodies directed against Chk1 (1:250 dilution; Santa Cruz Biotechnology, Santa Cruz, CA) or Chk1-S345-P (Cell Signaling Technology) followed by a horseradish peroxidase-linked anti-mouse secondary antibody (1:1000 dilution; Amersham Biosciences). Proteins were detected with the use of the enhanced chemiluminescence reagent (Pierce). All Western blots were performed at least three times, and results of a typical experiment are shown.
Luciferase Assays-Transient transfections of U2OS-ATRkd cells for luciferase measurement were performed using electroporation as described previously (27) using 5 g of either pCMV-Vpr or 5 g of pCMV-thy and 5 g of LTR HIV-1 -Luc (27) . After electroporation, cells were plated at a density of 1 ϫ 10 6 /10 cm dish. At 48 h after the transfection cells were lysed and assayed for luciferase activity with a commercially available luciferase assay kit (Promega Corp.) using a LumiCount microplate reader (Packard Instrument Co.). The luciferase FIG. 1. Defective lentiviral vectors. For simplicity, only viral sequences are shown, and bacterial sequences were omitted. ⌿, HIV-1 packaging sequence; RRE, rev-responsive element; CMV, cytomegalovirus immediate-early promoter; IRES, internal ribosome entry site from the encephalomyocarditis virus. Vector production was accomplished by co-transfecting pHR-GFP or pHR-VPR with pCMV⌬R8.2⌬Vpr and pCMV-VSVG using calcium phosphate-mediated transfection. assay was performed using the following settings: photomultiplier tube ϭ 1,100 V; gain level ϭ 5.0; read length ϭ 0.5 s. Each experiment was performed in triplicate, and each measurement was the average of triplicate readings. Luciferase light units were normalized to 1 mg of protein content (Bio-Rad).
RNAi-mediated Knockdown-RNAi-mediated knockdown of Chk1 was performed as described in (37) . ATR RNAi-mediated knockdown was performed as described in Casper et al. (14) . The 19-nucleotide targets for short, interfering RNAs (siRNAs) are as follows: RNAi for ATR 9DS, 5Ј-AAC CTC CGT GAT GTT GCT TGA-3Ј (RNAi2; catalog number P-002090; Dharmacon, Boulder, CO); Chk1, 5Ј-AAG CGT GCC GTA GAC TGT CCA-3Ј (cat number P-002076; Dharmacon); control non-silencing RNAi, 5Ј-AAT TCT CCG AAC GTG TCA CGT-3Ј (catalog number 80 -1130; Qiagen, Valencia, CA). RNAi transfection efficiency was estimated by the percentage of fluorescence-positive cells in the control transfections with a fluorescein isothiocyanate-conjugated oligonucleotide. The efficiency of oligonucleotide transfection was always equal or higher than 80%.
RESULTS

ATR Function Is Required for Induction of Vpr-induced G 2
Arrest and Transactivation-To begin to probe the potential role of ATR in HIV-1 vpr-induced G 2 arrest we first used the pharmacological inhibitor of phosphatidylinositol 3-kinase-like protein kinases, LY294002 (38, 39) . HeLa cells were treated with either 50 M LY294002 in Me 2 SO or with Me 2 SO alone and then infected with either of the lentivirus vectors, pHR-VPR or pHR-GFP (Fig. 1) . These vectors encode either Vpr and GFP as a marker (pHR-Vpr) or GFP alone (pHR-GFP) and are packaged and titrated as described under "Experimental Procedures." Infection with pHR-Vpr, but not pHR-GFP, induces detectable G 2 arrest at 24 h post-infection and maximal G 2 arrest between 36 and 48 h when it reaches a plateau. 2 We analyzed the cell cycle profiles of infected cells at 36 h after infection using flow cytometry (Fig. 2) . The addition of LY294002 or caffeine (27) largely alleviated the Vpr-induced G 2 arrest. The addition of LY294002 or caffeine to pHR-GFP-transduced cells did not significantly affect their cell cycle profiles.
In a previous study, Bartz et al. (32) tested whether ATM Ϫ/Ϫ (AT) cell lines were able to arrest in response to Vpr. Bartz et al. (32) demonstrated that AT cells transfected with vpr arrest in G 2 with indistinguishable kinetics from ATM ϩ/ϩ cells. The results obtained using inhibitors taken together with those using ATM Ϫ/Ϫ cells suggest that a phosphatidylinositol 3-kinase-like protein other than ATM, presumably ATR, may be the mediator of Vpr-induced G 2 arrest. Therefore, we decided to use more direct experiments to test the role of ATR. A kinase deficient ATR that carries an Asp-2475 to Ala mutation within the catalytic domain of the protein was previously described (15, 16) . This ATR mutant, termed ATRkd (kinase-deficient), is defective in autophosphorylation and, when expressed in mammalian cells, acts as a dominant-negative regulator of wild-type ATR. U2OS7/ATRkd is a human osteosarcoma cell line that was stably transduced with a tetracycline-inducible ATRkd construct (16, 40) .
We utilized the U2OS/ATRkd cells to further investigate the role of ATR in Vpr-induced G 2 arrest (Fig. 3, panel A) . Expression of ATRkd was induced by the addition of 2 M doxycycline for 48 h. After doxycycline induction, the cells were infected with either pHR-VPR or pHR-GFP. Forty-eight hours after infection, we examined the cell cycle profiles of the infected cells. Uninduced U2OS/ATRkd cells displayed a normal cell cycle profile when not infected (Mock) or infected with pHR-GFP and displayed G 2 arrest when infected with pHR-VPR. Therefore, U2OS/ATRkd cells, in the absence of ATRkd induction, are sensitive to the cytostatic effect of Vpr. After induction of ATRkd expression with doxycycline, mock-infected cells displayed a normal cell cycle profile. However, under induction conditions, U2OS/ATRkd cells were significantly less sensitive to Vpr-induced G 2 arrest. To rule out the possibility that our observations may be specific to U2OS cells, we used an additional ATRkd-inducible cell line, GM847 (15) . Similar to U2OS/ ATRkd cells, GM847-ATRkd cells also became resistant to Vprinduced G 2 arrest upon ATRkd expression (data not shown). U2OS cells contain wild-type p53 whereas GM847 cells are transformed with SV40 large T antigen, which blocks p53 function. Consistent with prior observations (24), the p53 status of the cells does not appear to influence Vpr-induced G 2 arrest.
Viruses typically manipulate the host cell biology to ultimately benefit their propagation. The ability of HIV-1 to induce G 2 arrest through expression of vpr provides at least one known benefit to virus replication; that is, an increase in the transcriptional activity of the LTR. Numerous studies conclude that vpr acts as a moderate transactivator (26, 27, 29, 41, 42) . The ability of Vpr to transactivate the viral promoter is related to the fact that the LTR has features of a G 2 -responsive promoter. For example, induction of G 2 arrest with genotoxic agents provides a similar level of transactivation, as does vpr expression. Incubation of caffeine, a drug that alleviates DNA damage-dependent G 2 arrest, abrogates vpr-induced transactivation. We reasoned that if activation of ATR is the cause of vpr-induced transactivation and is the relevant target of caffeine-mediated transactivation reduction, then expression of ATRkd should inhibit such transactivation. To test the previous hypothesis, U2OS/ATRkd cells were treated with either control medium or 2 M doxycycline for 48 h to induce ATRkd (Fig. 3, panel B) . These cells were then transfected with pL-TR HIV-1 -luciferase (a reporter construct in which luciferase is expressed under the control of the LTR) and either a vpr expression vector (pCMV-VPR) or a control expression vector expressing Thy-1 marker (pCMV-thy). Forty-eight hours after transfection, cells were lysed, and the luciferase activity was measured and normalized to the protein content of the lysates. All values were normalized first to protein content and then to the transactivation value of the control plasmid transfected in the doxycycline-minus (uninduced) treatment (assigned a value of 1; Fig.  4, panel B) . The presence of ATRkd was concomitant with abrogation of the ability of vpr to increase the LTR transactivation.
Knockdown of ATR Leads to a Decrease in Vpr-induced G 2 Arrest-Although overexpression of ATRkd has been used to study ATR function, it remains formally possible that the presence of ATRkd, the dominant-negative mutant, affects the function of proteins other than ATR and, therefore, modulates other unsuspected checkpoint proteins. To induce inactivation of ATR by an independent method, we utilized RNAi. RNAi is a recently described mechanism utilized by eukaryotic cells to down-regulate the steady-state levels and/or the translation of specific mRNAs (43) (44) (45) . RNAi is accomplished by short (21-22 nucleotide) double-stranded RNA oligonucleotides (siRNAs) that are specific for the targeted mRNA.
We targeted ATR by transfecting synthetic, duplex RNA oligonucleotides as described under "Experimental Procedures." As controls we used an oligonucleotide duplex containing a nonspecific sequence and mock-transfection (no oligonucleotide). Detection of ATR protein by Western blot was performed on samples taken 72 h after the initial transfection (Fig. 4, panel A) . Densitometry scanning demonstrated a relative ATR protein down-regulation of 70% when using 9DS (ATR-specific) RNAi duplex when compared with the mock transfection. The transfection with control, nonspecific siRNA did not change ATR protein levels. Transduction of Vpr in 9DS-transfected cells either 48 (data not shown) or 72 h after the RNAi transfection yielded a significantly attenuated G 2 arrest when compared with either HeLa cells transfected with nonspecific sequence or untransfected cells (Fig. 4, panel B) . To rule out the possibility that this observation is due to specific depletion of the G 2 cells, we treated the ATR-transfected, Vprtransduced cells with the M-phase-arresting drug, nocodazole. We reasoned that nocodazole would retain in M those cells that were allowed to leave G 2 due to the ATR knockdown. However, if cells treated with ATR siRNA were dying in G 2 , treatment with nocodazole would not prevent such death. Treatment with nocodazole caused accumulation of the cells at the G 2 /M boundary. This observation demonstrates that in the absence of ATR function, Vpr-transduced cells are capable of entering mitosis.
Vpr Induces Chk1 Phosphorylation-Chk1 is a direct target for ATR in response to DNA damage. When cells sense DNA damage, ATR phosphorylates Chk1 on Ser-345 resulting in increased Chk1 activity. We wished to ascertain whether Vprinduced ATR activation would also result in phosphorylation of Chk1 on Ser-345. HeLa cells were infected with either pHR-VPR or pHR-GFP. Thirty-six hours post-infection, we analyzed the phosphorylation status of Chk1 by Western blot using a Ser-345-specific phospho-antibody (Fig. 5) . Mock-infected (Fig.  5, panel A; lane 1) and pHR-GFP-infected (Fig. 5, panel A; lane  3 ) cells only revealed faint bands corresponding to Chk1-S345-P. However, cells infected with pHR-VPR (Fig. 5, panel A; lane 2) or treated with doxorubicin (Fig. 5, panel A; lane 4) displayed a significant amount of Chk1-S345-P. Inhibition of ATR and ATM function by incubating cells with caffeine resulted in a significant (60% reduction by densitometry scanning), although not complete decrease of Chk1 phosphorylation (Fig. 5, panel B; lanes 1 and 2) . 2 Arrest-UCN-01 is a radiosensitizing agent that targets Chk1 as well as the related kinases Chk2 and c-Tak (46) . We hypothesized that inhibition of Chk1 by UCN-01 would result in reduction of G 2 arrest-induced by Vpr. To test this hypothesis, we treated HeLa cells with 200 nM UCN-01 (the concentration that is sufficient to completely inhibit Chk1 and c-TAK but not Chk2 (46)). Incubation with UCN-01 resulted in reduction of Vpr-induced G 2 arrest (Fig. 6 ), and consistent with previous observations (47) , it also reduced doxorubicin-induced G 2 arrest. Caffeine appeared to more effectively relieve the cell cycle block than UCN-01 for both Vpr and doxorubicin. As a negative control for alleviation of cell cycle arrest, we used taxol treatment. Taxol-treated cells arrest after entry into mitosis due to inability of microtubules to initiate chromosome separation (48) . Therefore, taxol induces a type of arrest that is not enforced by ATR or Chk1 and, therefore, should not be relieved by caffeine or UCN01. As expected neither UCN-01 nor caffeine had an effect on taxol-mediated cell cycle arrest.
Inhibition of Chk1 and Related Kinases with UCN-01 Relieves Vpr-induced G
Knockdown of Chk1 by RNAi Results in Reduction of Vprinduced G 2 Arrest-Because UCN-01 is not absolutely specific for Chk1 (46), we were unable to conclude that Chk1 is necessary for induction of G 2 arrest by Vpr. We addressed this question by performing knockdown of Chk1 by RNAi. A recent report indicated that using RNAi to target Chk1 results in a high level of Chk1 protein level knockdown and partial abrogation of Chk1-dependent checkpoint (37) . Using synthetic, duplex RNA oligonucleotides as described by Zhao et al. (37) , we achieved a 90% decrease in Chk1 protein level in HeLa cells ( Fig. 7; panel A) as evidenced by Western blot. To test whether Chk1 knockdown would result in attenuation of the Vpr-induced G 2 arrest, we proceeded to infect the above RNAi-targeted cells with either pHR-VPR or pHR-GFP and analyzed the resulting cell cycle profiles ( Fig. 7; panel B) . Cells treated with Chk1 siRNA demonstrated a significant reduction of G 2 arrest when compared with cells treated with no duplex or control duplex. Cells treated with Chk1-specific siRNA did not display appreciable changes in cell cycle profile when mock-infected ( Fig. 7; panel B) or when infected with pHR-GFP (data not shown). Therefore, Chk1 is necessary for the induction of G 2 arrest by vpr, and its role is consistent with the notion that Chk1 is a target of ATR (1) . DISCUSSION In the present study we investigated the potential role ATR in the biology of Vpr. Using pharmacological agents, a dominant-negative mutant, and RNA interference we have demon- strated that ATR activity is required for full induction of the Vpr-induced G 2 arrest. The events after activation of the ATR pathway by Vpr closely parallel those observed upon activation of the DNA damage checkpoint controlled by ATR. These events include phosphorylation of Chk1 and hyperphosphorylation of Cdc2. These observations suggest that the regulation of the transition between G 2 and M by Vpr is similar to that induced by DNA-damaging agents that specifically activate ATR.
It is not known whether Vpr actually causes DNA damage or whether, alternatively, it generates a signal that "mimics" DNA damage by activating one of the DNA damage sensors. Our previous observations suggest a possible difference between the DNA damage and Vpr-induced checkpoint activation pathways (27) . Inhibition of the checkpoint proteins in the context of DNA damage usually results in increased apoptosis. Our earlier observations demonstrated that inhibition of the Vpr-induced checkpoint by caffeine resulted in unexpectedly decreased apoptosis (27) .
The ATR and Chk1 knockdown experiments we present produced incomplete relief of the Vpr-induced G 2 arrest. This observation could be explained by the existence of an alternative or complementary signaling pathway that can also be activated by Vpr to induce G 2 arrest. An alternative, simpler explanation would be based on the fact that RNAi knockdowns were not complete (70% for ATR and 90% for Chk1). In light of the fact that pharmacological inhibition of either ATR with caffeine completely relieved the cell cycle block by Vpr, it appears more likely that the second explanation is true.
Previously, attempts have been made to study Vpr-biology in the fission yeast. In that system neither the knockout of the ATR/ATM homologue, Rad3, nor knockouts of the Chk1 and Chk2 homologues resulted in a reduction of the Vpr-induced growth defect (49) . It is possible that an alternative DNA damage-responsive system is activated in the fission yeast. Rad3 mutants in fission yeast are viable (50) , whereas the mec1 mutations in the budding yeast and ATR in human cells are lethal. It appears that mammalian ATR plays a role in patrolling for genomic integrity during normal replication. ATR deletion leads to apoptosis-independent chromosomal breakdown and expression of fragile sites (13, 14) . Rad3 deletion in Schizosaccharomyces pombe, however, does not compromise genomic integrity in the absence of exogenously induced genotoxic stress. Moreover in mammalian cells, ATR/ATM-mediated Chk1 activation requires breast cancer susceptibility gene-1 (BRCA1), whereas homologues are not known in yeast (51) . This suggests that there is an incomplete functional homology between the fission yeast Rad3 and the ATR signaling systems that may account for the observed differences.
A recent report (52) demonstrates that HIV-1 Vpr induces defects in nuclear lamin structure and consequent nuclear herniation with chromatin structure alterations. Vpr-induced changes in chromatin structure may lead to stalled DNA replication. ATR has recently emerged as a key sensor of incomplete replication status of mammalian cells (7, (53) (54) (55) . Therefore, the model proposed by De Noronha et al. (52) and the results presented here would be consistent with a scenario where Vpr causes nuclear herniations that slow down DNA synthesis, which in turn activates ATR.
In view of the above findings we propose the following model for the signaling induced by the Vpr. Via interaction with lamins and the subsequent nuclear herniation, Vpr induces alterations in the chromatin structure that lead to stalled replication. The alterations in chromatin structure and replication are sensed by ATR, which in turn activates Chk1. Further activation of the ATR/Chk1 cascade leads to inhibition of Cdc2, the key regulator of the G 2 /M transition. Likely candidates as the immediate inhibitors of Cdc2 may be Cdc25C (21) and Wee1 (56, 57). 
